

View Article Online View Journal

Dalton Transactions

Accepted Manuscript

This article can be cited before page numbers have been issued, to do this please use: A. Rodríguez-Bárzano, R. M. Lord, A. M. Basri, R. M. Phillips, J. Blacker and P. C. McGowan, *Dalton Trans.*, 2015, DOI:



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about *Accepted Manuscripts* in the **Information for Authors**.

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard <u>Terms & Conditions</u> and the <u>Ethical guidelines</u> still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.



www.rsc.org/dalton

RSCPublishing

Journal Name

COMMUNICATION

Cite this: DOI: 10.1039/x0xx00000x

Synthesis and anticancer activity evaluation of η^5 -C₅(CH₃)₄R ruthenium complexes bearing chelating diphosphine ligands[†]

Received 00th January 2012, Accepted 00th January 2012

DOI: 10.1039/x0xx00000x

www.rsc.org/

Published on 05 January 2015. Downloaded by UNIVERSITY OF OTAGO on 06/01/2015 14:01:09

A. Rodríguez-Bárzano,^{*a*} R. M. Lord,^{*a*} A. M. Basri,^{*a*} R. M. Phillips,^{*b*} A. J. Blacker^{*a*} and P. C. McGowan^{**a*}

The complexes [RuCp*(PP)Cl] (Cp* = C₅Me₅; [1], PP = dppm; [4], PP = Xantphos), [RuCp[#](PP)Cl] (Cp[#] = C₅Me₄(CH₂)₅OH; [2], PP = dppm; [5], PP = Xantphos) and [RuCp*(dppm)(CH₃CN)][SbF₆] [3] were synthesized and evaluated *in vitro* as anticancer agents. Compounds 1-3 gave nanomolar IC₅₀ values against normoxic A2780 and HT-29 cell lines, and were also tested against hypoxic HT-29 cells, maintaining their high activity. Complex 3 yielded an IC₅₀ value of 0.55 ± 0.03 μ M under a 0.1% O₂ concentration.

Numerous organometallic (η^6 -arene)-ruthenium complexes have been screened as anticancer agents with promising results, for instance, compounds of the types $[(\eta^6 \text{-arene})Ru(NN)Cl]^+$ (NN = chelating nitrogen ligands, especially ethylenediamine (en)), $^{1-3}$ [(η^6 arene)Ru(NO)CI (NO = 3'-fluorophenyl-3-(phenylamino)-2-buten-1-one),⁴ [(η^6 -arene)Ru(OO)X] (OO = 3-hydroxyflavone derivatives, X = Cl, Br or I)^{5, 6} or $[(\eta^6 \text{-arene})\text{Ru}(\text{pta})\text{Cl}_2]$ (RAPTA) (pta = 1,3,5triaza-7-phosphatricyclo [3.3.1.1] decane).7, 8 Samuelson and coworkers have published the use of η^6 -p-cymene ruthenium complexes with different diphosphines acting as either monodentate or chelating ligands, which showed good growth inhibitions against several cancer cell lines.⁹ In contrast, fewer examples of η^5 cyclopentadienyl (Cp) or pentamethylcyclopentadienyl (Cp*) compounds have been biologically evaluated. Sava reported the synthesis and activity against TS/A adenocarcinoma of the compounds $[(\eta^5-C_5H_5)Ru(pta)_2Cl]$ and $[(\eta^5-C_5Me_5)Ru(pta)_2Cl]$, as equivalents to the RAPTA complexes.¹⁰ Compounds of the type [$(\eta^5 -$ (PP 2 C_5H_5 Ru(PP)L][X]= × PPh_3 or 1.2bis(diphenylphosphino)ethane, L = planar nitrogen σ -bonded ligand and $X = CF_3SO_3$ or PF₆) have been synthesised by Moreno *et al.* and some of them show better cytotoxicities than cisplatin.¹¹⁻¹³ However, none of these Cp/Cp* ruthenium complexes has been tested under hypoxic conditions. Some diphosphines have demonstrated cytotoxicity against various cell lines,¹⁴ but it has been observed that, upon coordination to metals, diphosphines produce complexes with improved anticancer activity compared to the free ligands; a general hypothesis considers that the metal protects the ligands from oxidation before they interact with the corresponding biological target.15

Here we present the results obtained from cell line assays carried out under normoxic and hypoxic conditions with ruthenium complexes 1,1containing chelating diphosphine ligands such as bis(diphenylphosphino)methane 4,5-(dppm) and The bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos). complexes have general structures [RuCp*(PP)Cl] (1, PP = dppm; 4, PP = Xantphos), $[RuCp^{\#}(PP)Cl]$ (Cp[#] = C₅Me₄(CH₂)₅OH; **2**, PP = dppm; 5, PP = Xantphos) and $[RuCp*(PP)(CH_3CN)][SbF_6]$ (3, PP = dppm). We investigated the biological activity of both ligands and the effect of complexation. We were interested in assessing the impact of hydrophilic functionalisation of Cp* with an -OH group and the different cytotoxicities shown by analogous neutral and charged complexes. The anticancer activities were assessed against A2780 and HT-29 cell lines, for HT-29 both at 21% and 0.1% O2 (hypoxic conditions) concentrations.

Complexes 1 and 4 were synthesised from [RuCp*Cl₂]₂, which was obtained following literature methods.^{16, 17} A similar method was employed for compounds 2 and 5, starting from the novel [RuCp[#]Cl₂]₂ complex (Scheme 1). This in turn was prepared by reaction of (5-hydroxypentyl)-tetramethylcyclopentadiene¹⁸ with RuCl₃ in ethanol at reflux. Compounds $\mathbf{1}^{19, 20}$ and $\mathbf{4}^{21}$ had been previously reported, but not biologically tested. Complex 3 was obtained from complex 1, acetonitrile and $NaSbF_6$ in methanol at room temperature (Scheme 2). This method was adapted from the published synthesis of $[RuCp*(PP)(CH_3CN)][PF_6]$ complexes, where PP = chiral diphosphines.²² The structure of complex **3** was determined by single crystal X-ray diffraction. Compound 3 crystallised in a triclinic cell from pentane/chloroform, and the structural solution was performed in the space group $P\overline{1}$. The asymmetric unit comprises one molecule of compound 3, including the counterion SbF_6 . The molecular structure of **3** is shown in Figure 1 and selected bond lengths and angles are given in Table 1. Compound **3** presents the characteristic piano-stool geometry typical of η^5 - and η^6 -organometallic ruthenium species. The N(1)-C(11) triple bond length is 1.153(2) Å.

The cytotoxic activities of compounds 1-5, along with cisplatin, dppm and Xantphos were tested on the A2780 and HT-29 cell lines after five-day exposures at 37 °C and 21% O₂. The IC₅₀ results are shown in Table 2. The most active complexes were those formed from dppm, 1, 2 and 3, all with better cytotoxicities, in the nanomolar range, than cisplatin for both HT-29 and A2780 cell lines.

Published on 05 January 2015. Downloaded by UNIVERSITY OF OTAGO on 06/01/2015 14:01:09.

Dppm was active by itself, with IC_{50} values below 1.5 μ M. However, ¹H and ³¹P NMR spectroscopy experiments in deuterated DMSO showed no de-coordination of dppm from complexes 1 and 3 after five days. The observation that diphosphines do not dissociate is further reinforced by the fact that complexes 4 and 5 gave moderate to good activities, which are not due to a possible release of the ligand, because Xantphos did not show anticancer behaviour on its own. This contradicts the previous hypothesis that the activities of these types of diphosphine complexes depend on possible de-coordinations of the ligands.¹⁵ The extremely different behavior of dppm and Xantphos provides interesting material for further future studies. Complexes 4 and 5 were more active against A2780 cells, with IC₅₀ values close to cisplatin. The presence of the (CH₂)₅OH chain in the Cp[#] compounds 2 and 5 produced no great effect on their anticancer activities, compared to those of the Cp* complexes 1 and 4. The best cytotoxicity was observed for the positively charged complex 3.



Scheme 1. General synthesis of complexes 1, 2, 4 and 5.



Scheme 2. Synthesis of complex 3.



Figure 1. ORTEP structure of complex 3 (cation) with thermal ellipsoids set at 50% probability. Hydrogen atoms omitted for clarity.

To assess the extent of hydrolysis²³ in complexes **1** and **3**, 10 mM samples of both complexes in 0.6 ml of deuterated solvent (90% deuterated DMSO + 10% deuterium oxide) were prepared in NMR tubes and analysed by ¹H NMR spectroscopy every 24 hours during five days at room temperature. A new set of peaks at 5.14 and 1.61 ppm appeared gradually in both samples (see

Fig. S1 in the ESI). The new species formed, after five days, in 48% yield from complex 1 and in 67% yield from complex 3. Mass spectrometry of this new species showed the same peaks observed for the chloride complex 1, where the chloride ligand was lost. By inference, the new species is believed to be the aqua species, which entails that monocationic complex 3 hydrolyses to a higher extent under the same conditions, and this coincides with its higher anticancer activity.

Table 1. Selected bond lengths [Å] and angles $[\circ]$ in the structure of compound **3** with s.u.s. in parenthesis.

$P_{11}(1) - N(1)$	2 0775(16)
$\operatorname{Ku}(1)$ - $\operatorname{IV}(1)$	2.0775(10)
$\operatorname{Ru}(1)$ -P(1)	2.3201(6)
Ru(1)-P(2)	2.3503(6)
N(1)-C(11)	1.153(2)
C(11)-C(12)	1.481(3)
Ru(1)-Ring Centroid	1.884
Ru(1)-C(Cp*)	2.25226
P(1)-Ru(1)-P(2)	71.626(19)
N(1)-C(11)-C(12)	178.5(2)
C(11)-N(1)-Ru(1)	178.90(16)
P(2)-C(13)-P(1)	93.53(8)

Table 2 gives the IC₅₀ results obtained for the most active compounds 1-3 against hypoxic HT-29 cells at an oxygen concentration of 0.1%. Cancerous cells are known to proliferate within hypoxic environments, with oxygen content below 2%,24 therefore hypoxic experiments tend to reproduce the conditions found in human solid tumours. Apart from cisplatin, whose activity remains practically unmodified, tirapazamine, a drug known to be hypoxia sensitive,²⁵ was also employed as reference. Interestingly, the IC_{50} of dppm under hypoxic conditions increased considerably from 1.47 µM to 17.19 µM. A possible explanation for this is that the active species might be an oxidized form of dppm. However, Samuelson et al. have reported that, while dppm is moderately active against H460 lung cells (IC₅₀ = 18.2 μ M), mono-oxidised dppm shows no cytotoxic activity (IC₅₀ > 250 μ M),⁹ and similar conclusions had been drawn by Sadler *et al.*¹⁴ The activities of complexes 1-**3** improved slightly at a low O_2 concentration. Complex **3** showed again the best performance, with an IC₅₀ of 0.55 ± 0.03 µM, and is of particular significance and interest.

Table 2. IC_{50} values for complexes 1-5 along with cisplatin, tirapazamin, dppm and Xantphos. The drugs were incubated for 5 days at 37 °C.

	$IC_{50}\left(\mu M\right)$ at 21% O_{2}				IC ₅₀ (µM) at 0.1% O ₂	
Compound	A2780	±	HT-29	±	HT-29	±
Cisplatin	1.4	0.3	2.52	0.09	2.4	0.4
Tirapazamine	-	-	31	3	2.8	0.4
dppm	1	1	1.47	0.02	17.19	0.08
1	1.1	0.2	0.73	0.05	0.66	0.03
2	0.9	0.1	0.791	0.007	0.76	0.03
3	0.70	0.02	0.61	0.01	0.55	0.03
Xantphos	>250	-	>250	-	-	-
4	3.6	0.4	10.1	0.5	-	-
5	4.0	0.3	11.9	0.7	-	-

Conclusions

Journal Name

In summary, a series of Cp*-based diphosphine ruthenium complexes (1-5) was prepared and biologically tested against A2780 and HT-29 cancerous cell lines. Both normoxic and hypoxic studies showed activities in the nanomolar range. The best anticancer activity was obtained with complex 3, which maintained a low IC₅₀ value even under hypoxic conditions with 0.1% O₂ concentration, and showed a higher degree of hydrolysis than its neutral analogue 1 under the same conditions. Future studies could include cationic versions of 2, 4, 5 and similar complexes to check whether they are generally more effective. Testing other free and coordinated phosphines and phosphine oxides could shed some light on the effect that the oxidation state and structure of the ligand have on cytotoxic activity.

Notes and references

^{*a*} School of Chemistry, University of Leeds, Woodhouse Lane, Leeds, LS2 9JT, UK. Fax: +44 (0)113 343 6565; Tel: +44 (0)113 343 6404; E-mail: <u>P.C.McGowan@leeds.ac.uk</u>

^b The Institute of Cancer Therapeutics, University of Bradford, Bradford, BD7 1DP, UK. Fax: +44 (0)127 423 3234; Tel: +44 (0)127 423 5367; E-mail: R.M.Phillips@bradford.ac.uk

† We wish to acknowledge Technology Strategy Board for funding.

Electronic Supplementary Information (ESI) available: experimental procedures for compounds, cell line experimental and crystal structure determination details (CCDC 957987). See DOI: 10.1039/c000000x/

- R. E. Morris, R. E. Aird, P. del Socorro Murdoch, H. Chen, J. Cummings, N. D. Hughes, S. Parsons, A. Parkin, G. Boyd, D. I. Jodrell and P. J. Sadler, *J. Med. Chem.*, 2001, 44, 3616-3621.
- A. Habtemariam, M. Melchart, R. Fernández, S. Parsons, I. D. H. Oswald, A. Parkin, F. P. A. Fabbiani, J. E. Davidson, A. Dawson, R. E. Aird, D. I. Jodrell and P. J. Sadler, *J. Med. Chem.*, 2006, **49**, 6858-6868.
- S. J. Dougan and P. J. Sadler, Chimia Int. J. Chem., 2007, 61, 704-715.
- S. J. Lucas, R. M. Lord, R. L. Wilson, R. M. Phillips, V. Sridharan and P. C. McGowan, *Dalton Trans.*, 2012, **41**, 13800-13802.
- A. Kurzwernhart, W. Kandioller, C. Bartel, S. Bachler, R. Trondl, G. Muhlgassner, M. A. Jakupec, V. B. Arion, D. Marko, B. K. Keppler and C. G. Hartinger, *Chem. Comm.*, 2012, 48, 4839-4841.
- A. Kurzwernhart, W. Kandioller, E. A. Enyedy, M. Novak, M. A. Jakupec, B. K. Keppler and C. G. Hartinger, *Dalton Trans.*, 2013, 42, 6193-6202.
- C. S. Allardyce, P. J. Dyson, D. J. Ellis and S. L. Heath, *Chem. Comm.*, 2001, 1396-1397.
- W. Han Ang and P. J. Dyson, Eur. J. Inorg. Chem., 2006, 2006, 4003-4018.
- S. Das, S. Sinha, R. Britto, K. Somasundaram and A. G. Samuelson, J. Inorg. Biochem., 2010, 104, 93-104.
- D. N. Akbayeva, L. Gonsalvi, W. Oberhauser, M. Peruzzini, F. Vizza, P. Bruggeller, A. Romerosa, G. Sava and A. Bergamo, *Chem. Comm.*, 2003, 264-265.

- M. H. Garcia, T. S. Morais, P. Florindo, M. F. M. Piedade, V. Moreno, C. Ciudad and V. Noe, *J. Inorg. Biochem.*, 2009, 103, 354-361.
- V. Moreno, J. Lorenzo, F. X. Avilés, M. H. Garcia, J. P. Ribeiro, T. S. Morais, P. Florindo and M. P. Robalo, *Bioinorg.Chem. Appl.*, 2010, 1-11.
- V. Moreno, M. Font-Bardia, T. Calvet, J. Lorenzo, F. X. Avilés, M. H. Garcia, T. S. Morais, A. Valente and M. P. Robalo, J. Inorg. Biochem., 2011, 105, 241-249.
- S. J. Berners-Price, R. E. Norman and P. J. Sadler, J. Inorg. Biochem., 1987, 31, 197-209.
- S. J. Berners-Price, C. K. Mirabelli, R. K. Johnson, M. R. Mattern, F. L. McCabe, L. F. Faucette, C.-M. Sung, S.-M. Mong, P. J. Sadler and S. T. Crooke, *Cancer Res.*, 1986, 46, 5486-5493.
- N. Oshima, H. Suzuki and Y. Moro-Oka, Chem. Lett., 1984, 13, 1161-1164.
- T. D. Tilley, R. H. Grubbs and J. E. Bercaw, *Organometallics*, 1984, 3, 274-278.
- A. J. Blacker, S. Brown, B. Clique, B. Gourlay, C. E. Headley, S. Ingham, D. Ritson, T. Screen, M. J. Stirling, D. Taylor and G. Thompson, *Org. Process Res. Dev.*, 2009, 13, 1370-1378.
- U. Koelle and J. Kossakowski, J. Organomet. Chem., 1989, 362, 383-398.
- M. I. Bruce, B. G. Ellis, P. J. Low, B. W. Skelton and A. H. White, *Organometallics*, 2003, 22, 3184-3198.
- K. Takahashi, M. Yamashita, Y. Tanaka and K. Nozaki, *Angew. Chem. Int. Ed.*, 2012, **51**, 4383-4387.
- F. Morandini, A. Dondana, I. Munari, G. Pilloni, G. Consiglio, A. Sironi and M. Moret, *Inorg. Chim. Acta*, 1998, 282, 163-172.
- F. Wang, H. Chen, S. Parsons, I. D. H. Oswald, J. E. Davidson and P. J. Sadler, *Chem. Eur. J.*, 2003, 9, 5810-5820.
- J. A. Bertout, S. A. Patel and M. C. Simon, *Nat. Rev. Cancer*, 2008, 8, 967-975.
- R. F. Anderson, S. S. Shinde, M. P. Hay, S. A. Gamage and W. A. Denny, J. Am. Chem. Soc., 2002, 125, 748-756.

Dalton Transactions Accepted Manuscript





81x41mm (300 x 300 DPI)